Abstract
A group of novel N-1-substituted indazole-3-carboxamide derivatives were synthesized and evaluated as inhibitors of poly(ADP-ribose)polymerase-1 (PARP-1). A structure-based design strategy was applied to a weakly active unsubstituted 1H-indazole-3-carboxamide 2, by introducing a three carbon linker between 1H-indazole-3-carboxamide and different heterocycles, and led to compounds 4 [1-(3-(piperidine-1-yl)propyl)-1H-indazole-3-carboxamide, IC 50=36μm] and 5 [1-(3-(2,3-dioxoindolin-1-yl)propyl)-1H-indazole-3-carboxamide, IC 50= 6.8μm]. Compound 5 was evaluated in rats for its protective action against diabetes induced by a treatment with streptozotocin, a known diabetogenic agent. In addition to preserving the ability of the pancreas to secrete insulin, compound 5 was also able to attenuate the ensuing hyperglycemic response to a significant extent. © 2011 John Wiley & Sons A/S.
Author supplied keywords
Cite
CITATION STYLE
Patel, M. R., Pandya, K. G., Lau-Cam, C. A., Singh, S., Pino, M. A., Billack, B., … Talele, T. T. (2012). Design and Synthesis of N-Substituted Indazole-3-Carboxamides as Poly(ADP-ribose)polymerase-1 (PARP-1) Inhibitors. Chemical Biology and Drug Design, 79(4), 488–496. https://doi.org/10.1111/j.1747-0285.2011.01302.x
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.